Chief Financial Officer, Azura Ophthalmics
| Role | Organisation | Sources |
|---|---|---|
| Chief Financial Officer | Azura Ophthalmics | Brandon BioCatalyst portfolio (21 Sep 2022), Brandon BioCatalyst portfolio (17 Aug 2022), Brandon Capital portfolio |
Stories naming Ashwin Agarwal. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Eye-drug developer Azura Ophthalmics, working from Melbourne and Tel Aviv, has assembled a seven-member scientific advisory board of ophthalmology specialists to guide clinical development of its lead candidate AZR-MD-001.
Azura Ophthalmics won a CUREator grant to fund a two-stage study of its AZR-MD-001 candidate for contact lens discomfort, extending pilot research conducted with UNSW; the incubator program is run by Brandon BioCatalyst.